Drug Profile

Ulixacaltamide - Praxis Precision Medicine

Alternative Names: PRAX-944; Z 944

Latest Information Update: 26 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zalicus
Developer Praxis Precision Medicines; Taro Pharmaceuticals USA
Class Analgesics; Antiepileptic drugs; Benzamides; Piperidines; Small molecules
Mechanism of Action T-type calcium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preregistration Essential tremor
Phase II Epilepsy
No development reported Pain

Most Recent Events

20 Feb 2026 Praxis Precision Medicines announces intention to launch ulixacaltamide in Essential tremor
20 Feb 2026 Preregistration for Essential tremor in USA (PO)
04 Feb 2026 Phase-III clinical trials in Essential tremor is ongoing in USA (PO) (NCT06087276)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com